Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) EBITDA (2024 - 2025)

Xilio Therapeutics' EBITDA history spans 2 years, with the latest figure at -$16.3 million for Q3 2025.

  • For Q3 2025, EBITDA fell 16.17% year-over-year to -$16.3 million; the TTM value through Sep 2025 reached -$58.5 million, changed N/A, while the annual FY2024 figure was -$58.2 million, 23.77% up from the prior year.
  • EBITDA for Q3 2025 was -$16.3 million at Xilio Therapeutics, down from -$15.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$13.1 million in Q4 2024 and bottomed at -$17.2 million in Q1 2024.